143 related articles for article (PubMed ID: 25211092)
61. Do hepatitis C Virus genotypes influence liver dysfunction following rituximab-containing regimens in patients with diffuse large B cell lymphoma?
Toshikuni N; Maeda T; Ueda Y
Acta Haematol; 2012; 127(3):178-81. PubMed ID: 22343527
[No Abstract] [Full Text] [Related]
62. [Radioimmunotherapy for B-cell lymphoma].
Tobinai K
Rinsho Ketsueki; 2006 Jun; 47(6):463-70. PubMed ID: 16862974
[No Abstract] [Full Text] [Related]
63. Monthly administration of rituximab is useful for patients with ocular adnexal mucosa-associated lymphoid tissue lymphoma.
Mino T; Mihara K; Yoshida T; Takihara Y; Ichinohe T
Blood Cancer J; 2014 Sep; 4(9):e245. PubMed ID: 25215661
[No Abstract] [Full Text] [Related]
64. Treatment of cutaneous lymphoid hyperplasia with the monoclonal anti-CD20 antibody rituximab.
Martin SJ; Duvic M
Clin Lymphoma Myeloma Leuk; 2011 Jun; 11(3):286-8. PubMed ID: 21658657
[TBL] [Abstract][Full Text] [Related]
65. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma.
Lossos IS; Morgensztern D; Blaya M; Alencar A; Pereira D; Rosenblatt J
Leuk Lymphoma; 2007 Aug; 48(8):1630-2. PubMed ID: 17701596
[No Abstract] [Full Text] [Related]
66. Small-cell lung cancer arising after chemotherapy for a patient with lymphoma of pulmonary mucosa-associated lymphoid tissue-a case report.
Nakao M; Oguri T; Maeno K; Kusumoto S; Ota C; Takakuwa O; Uemura T; Ozasa H; Iwashima Y; Miyazaki M; Kutsuna T; Nakamura A; Inagaki H; Sato S; Ueda R
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1711-4. PubMed ID: 19838033
[TBL] [Abstract][Full Text] [Related]
67. Autoimmune phenomena in untreated and treated marginal zone lymphoma.
Grabska J; Dasanu CA
Expert Opin Pharmacother; 2011 Oct; 12(15):2369-79. PubMed ID: 21679092
[TBL] [Abstract][Full Text] [Related]
68. Waxing and waning intravascular large cell lymphoma with widespread organ infiltration.
Vos JM; Bordbar A; Vet RJ; Pals ST; Kater AP
Leuk Lymphoma; 2011 Apr; 52(4):705-8. PubMed ID: 21190427
[No Abstract] [Full Text] [Related]
69. Favourable response to rituximab by an ocular adnexal primary lymphoma.
Luque Valentin-Fernandez ML; Alvarez Rodríguez F; Rodríguez Jiménez I
Arch Soc Esp Oftalmol; 2016 Nov; 91(11):539-542. PubMed ID: 27125186
[TBL] [Abstract][Full Text] [Related]
70. Unusual cystic presentation of pulmonary nodular amyloidosis associated with MALT-type lymphoma.
Lantuejoul S; Moulai N; Quetant S; Brichon PY; Brambilla C; Brambilla E; Ferretti GR
Eur Respir J; 2007 Sep; 30(3):589-92. PubMed ID: 17766635
[TBL] [Abstract][Full Text] [Related]
71. [Synchronic MALT lymphoma and carcinoid tumor of the ileum].
Berroa de la Rosa E; Casadiego Matarranz L; Aparicio Duque R; Peñarrubia Ponce MJ; Ortiz de Solórzano Aurusa J; Fernández Salazar L
Gastroenterol Hepatol; 2014 Feb; 37(2):95-6. PubMed ID: 24029173
[No Abstract] [Full Text] [Related]
72. Persistent CD20-negative primary cutaneous marginal zone lymphoma after treatment with intralesional rituximab therapy.
Lozzi GP; Coletti G; Peris K
J Am Acad Dermatol; 2008 Nov; 59(5 Suppl):S110-2. PubMed ID: 19119114
[No Abstract] [Full Text] [Related]
73. Rituximab monotherapy for splenic marginal zone lymphoma with villous lymphocytes: report on long-term disease control for two patients with recurrence after splenectomy.
Debiasi M; Hehnemann M; Garicochea B
Sao Paulo Med J; 2010 Dec; 128(6):375-7. PubMed ID: 21308163
[TBL] [Abstract][Full Text] [Related]
74. Successful rituximab monotherapy for API2-MALT1 fusion positive primary mucosa-associated lymphoid tissue lymphoma of the transverse colon in a patient with liver cirrhosis.
Yamada M; Kawahara H; Shiroeda H; Tsuchishima M; Masaki Y; Sato K; Takase S
Scand J Gastroenterol; 2008; 43(6):761-4. PubMed ID: 18569996
[No Abstract] [Full Text] [Related]
75. Intrapericardial and intrapleural administration of rituximab to a patient with marginal zone lymphoma.
Boguradzki P; Drozd-Sokolowska JE; Wieczorek J; Kowalik R; Starczewska M; Krol M; Kobylecka M; Opolski G; Wiktor-Jedrzejczak W
Acta Haematol; 2013; 130(3):169-71. PubMed ID: 23735747
[TBL] [Abstract][Full Text] [Related]
76. Rituximab for treating CD20+ prostate cancer with generalized lymphadenopathy: a case report and review of the literature.
Dalgleish A; Featherstone P; Vlassov V; Rogosnitzky M
Invest New Drugs; 2014 Oct; 32(5):1048-52. PubMed ID: 24442368
[TBL] [Abstract][Full Text] [Related]
77. [Clinicopathologic features of primary thymic extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue type].
Sun L; Shi HY; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 Apr; 41(4):234-8. PubMed ID: 22800518
[TBL] [Abstract][Full Text] [Related]
78. Intratumoral but not systemic delivery of CpG oligodeoxynucleotide augments the efficacy of anti-CD20 monoclonal antibody therapy against B cell lymphoma.
Betting DJ; Yamada RE; Kafi K; Said J; van Rooijen N; Timmerman JM
J Immunother; 2009; 32(6):622-31. PubMed ID: 19483647
[TBL] [Abstract][Full Text] [Related]
79. Primary cutaneous marginal zone B-cell lymphoma: An atypical case.
Velázquez D; de Pablo P; García D; Ramírez JR
Dermatol Online J; 2010 Dec; 16(12):5. PubMed ID: 21199631
[TBL] [Abstract][Full Text] [Related]
80. Immunotherapy for low-grade non-hodgkin secondary lymphoma of the orbit.
Esmaeli B; Murray JL; Ahmadi MA; Naderi A; Singh S; Romaguera J; White CA; McLaughlin P
Arch Ophthalmol; 2002 Sep; 120(9):1225-7. PubMed ID: 12215104
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
